Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway

Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway

Increases in glucose production and decreases in hepatic glycogen storage induce glucose metabolic abnormalities in type 2 diabetes (T2DM). Empagliflozin, a sodium-dependent glucose transporter 2 (SGLT2) inhibitor, is an effective hypoglycemic drug; however, the effects of empagliflozin on hepatic g...

Full description

Bibliographic Details
Main Authors: Xiaochen Yu, Ziyu Meng, Ting Fang, Xiaohuan Liu, Ying Cheng, Linxin Xu, Xiangyang Liu, Xiaoyu Li, Mei Xue, Ting Li, Bei Sun, Liming Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Physiology
Subjects:
SGLT2 inhibitor
empagliflozin
gluconeogenesis
glycogenesis
AMPK/CREB/GSK3β signalling pathway
Online Access:https://www.frontiersin.org/articles/10.3389/fphys.2022.817542/full

Internet

https://www.frontiersin.org/articles/10.3389/fphys.2022.817542/full

Similar Items